JURISDICTION REPORT: MALAYSIA
PATENT ACT AMENDMENTS—IMPACT ON BIOTECHNOLOGY PATENTING
Oon Yen Yen Henry Goh & Co Sdn Bhd
Following enforcement of the amended Patent Regulations, reformation of Malaysia’s IP laws continues with the new provisions and amendments proposed to the Patents Act scheduled to be tabled in Parliament in June 2011.
Te Patents (Amended) Act 2011 contains many new provisions and enhancements that will be directly beneficial for the local biotechnology industry. Tis is very much in line with phase II of Malaysia’s National Biotechnology Policy announced by then Prime Minister, Tun Abdullah Badawi, in 2005. In phase II (2011 to 2015), emphasis is placed on the development of human capital for the discovery and development of new drugs based on natural resources—protection of IP arising from such development is essential.
A new provision has now been proposed that allows the government to grant rights for the manufacture, export and import of generic drugs without the prior consent of patent owners. Tis is an expansion to the existing provisions for generic drugs in the act (e.g. compulsory licence) and is as provided for under the Doha Declaration (paragraphs 1(a) and 2(a) of the TRIPS agreement) of which Malaysia is a party. When implemented, this provision potentially allows for the import of generics during a national emergency, and in circumstances of extreme urgency, also the manufacture and/or export of generics from Malaysia to any foreign country in the interest of public health.
Clarifying provisions to the existing Limitation of Rights of patent owners have also been proposed. Section 37(1A) of the act currently provides for a Bolar-type exemption with regards to acts done in relation to the drug development and submission of information for regulatory approvals. It has now been proposed to expand Section 37 to include further provisions exempting all acts done in the private sphere (non-commercial acts) as well as acts done for experimental purposes (e.g. research and development).
Provisions to exempt from infringement the agricultural use of plants (including plant propagating material) or animals (including breeding stock or other animal reproductive material) by farmers have been proposed. ‘Agriculture’ has also been included in the new definition of industrial applicability (amended Section 16), i.e. an invention will be considered industrially applicable if it can be made and/or used in any kind of industry, including agriculture.
Patent term extensions similar to those provided by the US Patent and
Trademarks Office have now been provided for in the proposed Patent (Amended) Act 2011. When implemented, this will allow for an extension of the patent term by up to two years, for any delays in prosecution on the part of the Malaysian Intellectual Property Office that cause the pendency
60 World Intellectual Property Review May/June 2011
period (between filing date and date of grant) of a patent application to exceed four years.
Te extension term will exclude any delays on the part of the applicant. Examples of acts construed as delays on the part of the applicant under new Section 35C of the act include applications for deferment for requesting substantive examination (and/or providing information and documents in respect of a substantive examination request), requests for extension of time, application for reinstatement to enter national phase (failure to meet 30-month deadline), voluntary amendments or voluntary divisional applications.
Specific provisions to define biotechnological inventions, biological material, modified biological material, essentially biological processes, microbiological processes, micro-organisms and modified micro-organisms have been proposed in the amended act, in line with those set out in the European Patent Convention and European Union Directive on Biotechnological Inventions.
It is hoped that the above amendments signal Malaysia’s long-awaited accession to the Budapest Treaty, which has been pending since the year 2006. Te treaty concerns the deposition of biological materials (including micro-organisms) with International Depository Authorities (IDA) in order to meet the enabling disclosure requirement of patenting. Insufficiency of disclosure is one of the possible grounds for invalidation of a Malaysian patent. Generally, it is impossible to sufficiently disclose an invention either directed at or requiring the use of biological materials merely by way of written description. Tis is addressed by depositing a sample of the material(s) with an IDA. All parties to the treaty recognise a deposit made in any IDA, which will be treated as sufficient for patent purposes in all member states.
Although not compulsory, it will be beneficial for Malaysia to form an IDA, as this will greatly reduce patent filing costs for local inventors. Presently, it is necessary for local inventors to deposit biological materials with foreign IDAs at high cost. Dialogue between the government and local research institutes and universities on the formation of an IDA started in June 2007. Selection of an existing facility hosted at a local research institute or university for ratification as an IDA by the World Intellectual Property Organization (WIPO) is expected in the near future.
On the whole, the proposed amendment to the Patents Act is a positive move by the government to enhance the local IP regime and it is hoped that the provisions outlined above will prove to be a growth catalyst for Malaysia’s biotechnology industry.
Oon Yen Yen is business development manager and a registered patent agent at Henry Goh & Co Sdn Bhd. She can be contacted at:
yen@henrygoh.com
www.worldipreview.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84